CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, released an update on its ongoing clinical study evaluating Berubicin for the treatment of recurrent GBM, an aggressive and incurable form of brain cancer. According to the report, the company continues to see rapid progression and acceleration of enrollment for the study, with 180 patients of the 243 expected currently enrolled across 46 clinical trial sites. In addition, CNS has documented the necessary number of patients reaching the primary efficacy endpoint, or overall survival, to conduct preplanned interim analysis. Topline data from the interim analysis should be available by the end of this year, which is also when the company expects the study will conclude. “Enrolling patients in an orphan disease trial is always a challenge, and that’s why we are thrilled with the rate of enrollment in this potentially pivotal study,” said CNS Pharmaceuticals CEO John Climaco in the press release. “The robust interest and enthusiasm among our investigators and patients reflect the pressing need to develop treatment options for patients with GBM. Addressing this devastating disease continues to be the driving force for our team.”

In addition, the company announced that Climaco will be featured in a live, moderated fireside chat on Benzinga’s upcoming Virtual Biotech Conference. The conference is slated for Aug. 3, 2023; the fireside chat will begin at 11:35 a.m. ET. Benzinga’s Virtual Biotech Conference spotlights biotech leaders and features the hottest companies in the biotech space today.

To view the fireside chat, visit https://ibn.fm/bDZmF

To view the full press releases, visit https://ibn.fm/TWIA6 and https://ibn.fm/E3Dof

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme, an aggressive and incurable form of brain cancer. For more information about the company, please visit www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork